title: In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.
authors.affiliation: Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA. yan.li@astrazeneca.com
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Diansong
authors.initials: D
authors.lastname: Zhou
authors.forename: Stephen S
authors.initials: SS
authors.lastname: Ferguson
authors.forename: Peter
authors.initials: P
authors.lastname: Dorff
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Simpson
authors.forename: Scott W
authors.initials: SW
authors.lastname: Grimm